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Aims We previously reported that in the EMPA-REG OUTCOMEw trial, empagliflozin added to standard of care reduced the
risk of 3-point major adverse cardiovascular events, cardiovascular and all-cause death, and hospitalization for heart
failure in patients with type 2 diabetes and high cardiovascular risk. We have now further investigated heart failure
outcomes in all patients and in subgroups, including patients with or without baseline heart failure.
Methods
and results
Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Seven thousand and twenty
patients were treated; 706 (10.1%) had heart failure at baseline. Heart failure hospitalization or cardiovascular death
occurred in a significantly lower percentage of patients treated with empagliflozin [265/4687 patients (5.7%)] than
with placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95% confidence interval: 0.55–0.79); P, 0.001],
corresponding to a number needed to treat to prevent one heart failure hospitalization or cardiovascular death of
35 over 3 years. Consistent effects of empagliflozin were observed across subgroups defined by baseline characteristics,
including patients with vs. without heart failure, and across categories of medications to treat diabetes and/or heart
failure. Empagliflozin improved other heart failure outcomes, including hospitalization for or death from heart failure
[2.8 vs. 4.5%; HR: 0.61 (0.47–0.79); P, 0.001] and was associated with a reduction in all-cause hospitalization [36.8 vs.
39.6%; HR: 0.89 (0.82–0.96); P ¼ 0.003]. Serious adverse events and adverse events leading to discontinuation were
reported by a higher proportion of patients with vs. without heart failure at baseline in both treatment groups, but were
no more common with empagliflozin than with placebo.
Conclusion In patients with type 2 diabetes and high cardiovascular risk, empagliflozin reduced heart failure hospitalization and
cardiovascular death, with a consistent benefit in patients with and without baseline heart failure.
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Introduction
Heart failure is highly prevalent in patients with diabetes,1,2 occur-
ring in more than one in five patients with diabetes aged over 65
years.1 Patients with both diabetes and heart failure have a poor
prognosis, with a median survival of approximately 4 years.3
Glucose-lowering treatment options for patients with type 2 dia-
betes and heart failure are limited. In a meta-analysis, no benefit
on heart failure hospitalization or death was demonstrated with
more intensive vs. less intensive glucose control.4 Furthermore,
specific glucose-lowering medications have not been shown to
improve heart failure outcomes and some may actually have
deleterious effects.5– 8
Empagliflozin is a potent and selective inhibitor of the sodium
glucose cotransporter 2 (SGLT2) used in the treatment of type 2
diabetes. By inhibiting SGLT2, empagliflozin reduces renal glucose
reabsorption and increases urinary glucose excretion.9 In addition
to reducing hyperglycaemia, empagliflozin is associated with osmot-
ic diuresis, reductions in weight and blood pressure without
increases in heart rate,10 –17 and has favourable effects on markers
of arterial stiffness and vascular resistance,18 albuminuria,17 and
serum uric acid.10– 16
In the EMPA-REG OUTCOMEw trial, treatment with empagliflo-
zin added to standard of care reduced the primary composite
outcome of cardiovascular death, non-fatal myocardial infarction
or non-fatal stroke (3-point major adverse cardiovascular events),
cardiovascular death, hospitalization for heart failure, and overall
mortality compared with placebo in patients with type 2 diabetes
and high cardiovascular risk.19 Here we report further analyses of
the EMPA-REG OUTCOMEw trial with respect to heart failure out-
comes in the overall patient population and in subgroups, including
patients with investigator-reported heart failure at baseline, and the
effect of empagliflozin on hospitalization due to any cause.
Methods
Study design
The design of the EMPA-REG OUTCOMEw trial (NCT01131676) has
been described.19,20 Briefly, the study population comprised patients
with type 2 diabetes (with glycated haemoglobin 7.0–9.0% for
drug-naı¨ve patients and 7.0–10.0% for those on stable glucose-lowering
therapy), established cardiovascular disease, and estimated glomerular
filtration rate (eGFR) .30 mL/min/1.73 m2. Patients with investigator-
reported heart failure at baseline were allowed to participate without
any restriction regarding ejection fraction or New York Heart Associ-
ation (NYHA) class. Participants were randomized to receive empagli-
flozin 10 mg, empagliflozin 25 mg, or placebo once daily as addition to
standard of care. Throughout the trial (or after week 12 for glucose-
lowering medication), investigators were encouraged to treat cardiovas-
cular risk factors to achieve optimal standard of care according to local
guidelines. The trial continued until at least 691 patients experienced an
adjudicated event included in the primary outcome: first occurrence of
cardiovascular death, non-fatal myocardial infarction, or non-fatal
stroke (3-point major adverse cardiovascular events). Patients who
prematurely discontinued study medication continued to be followed
for ascertainment of cardiovascular outcomes and vital status.
The trial was conducted in accordance with the principles of the Dec-
laration of Helsinki and the International Conference on Harmonisation
Good Clinical Practice guidelines and was approved by local authorities.
An independent ethics committee or institutional review board ap-
proved the clinical protocol at every participating centre. All the patients
provided written informed consent before study entry.
Safety was assessed based on adverse events that occurred during
treatment or ≤7 days after the last intake of study medication, coded
using the Medical Dictionary for Drug Regulatory Activities (MedDRA)
version 18.0. Oedema, an adverse event of special interest, was assessed
through a search of adverse events defined using six MedDRA preferred
terms (fluid overload, fluid retention, generalized oedema, oedema, oe-
dema peripheral, peripheral swelling).
Outcomes
Definitions of the major clinical outcomes in the EMPA-REG OUTCOMEw
trial have been published.19 All cardiovascular outcome events and
deaths were prospectively adjudicated by two Clinical Events Commit-
tees (for cardiac and neurological events).19 Outcomes assessed
included hospitalization for heart failure, the composite outcome of
heart failure hospitalization or cardiovascular death (excluding fatal
stroke), recurrent heart failure hospitalization, investigator-reported
heart failure, introduction of loop diuretics, death from heart failure,
and all-cause hospitalization (defined as hospitalization due to any
adverse event). Subgroup analyses were performed in subgroups
defined by baseline characteristics, including the presence/absence of
investigator-reported heart failure.
Hospitalization for heart failure was defined as an event requiring at
least an admission to an in-patient unit or a 12 h stay in the emergency
department as a result of clinical manifestations of new or worsening
heart failure. These included dyspnoea, orthopnoea, paroxysmal noc-
turnal dyspnoea, oedema, pulmonary basilar crackles, jugular venous
distension, third heart sound or gallop rhythm, and radiological evidence
of worsening heart failure. An additional criterion was the need for
added or increased therapy that included (i) initiation or up-titration
of diuretics, inotropes, or vasodilator therapy and/or (ii) initiation of
mechanical or surgical therapy, such as mechanical circulatory support,
heart transplantation, or ventricular pacing to improve cardiac function,
and/or (iii) use of ultrafiltration, haemofiltration, or dialysis directed at
the treatment of heart failure.
Investigator-reported heart failure was based on the narrow standar-
dized MedDRA query (SMQ) ‘cardiac failure’ (defined in Table 1). This
narrow SMQ was also used to define whether a patient had heart failure
at baseline.
Statistical analysis
It was pre-specified that analyses would compare the pooled empagliflo-
zin dose groups vs. placebo. Treatment group differences in the risk
of an outcome were assessed using a Cox proportional hazards
model with treatment, age, sex, baseline body mass index, baseline
glycated haemoglobin, baseline eGFR, and region as factors. Subgroup
analyses included additional effects for a subgroup factor and a treat-
ment by subgroup factor interaction. Cumulative incidence function
estimates were corrected for non-cardiovascular mortality as a compet-
ing risk.21 Due to the declining numbers of patients at risk, cumulative
incidence plots have been truncated at 48 months. Numbers needed
to treat were computed from an estimate of the risk difference
based on an exponential model with a linearized (constant) hazard
over time.
The primary analyses were conducted following a modified
intent-to-treat approach in patients treated with at least one dose of
study drug. Each patient who did not have an event was censored on
the last day they were known to be free of the outcome. Secondary
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analyses included comparisons of the individual doses (empagliflozin
10 mg or 25 mg) vs. placebo. Pre-specified sensitivity analyses were per-
formed based on only those events that occurred during treatment or
≤30 days after a patient’s last intake of study drug (‘treated set plus
30 days’), and based on only those events that occurred during treatment
or ≤30 days after a patient’s last intake of study drug in patients who
received ≥30 days of study medication (cumulative) (‘on-treatment set’).
All analyses were performed on a nominal level of a ¼ 0.05 two sided
without adjustment for multiplicity. Statistical analyses were performed
using SASw version 9.4. All analyses were pre-specified except for:
analyses in the subgroups of patients with and without heart failure at
baseline of cardiovascular death, all-cause mortality, hospitalization
for heart failure, and adverse events; analyses in the subgroups of
patients by use of loop diuretics at baseline; introduction of loop
diuretics; hospitalization for heart failure by use of mineralocorticoid
receptor antagonists at baseline; recurrent events of heart failure
hospitalization or cardiovascular death (composite); and all-cause
hospitalization.
Results
Patients
A total of 7020 patients at 590 sites in 42 countries received at least
one dose of study drug. The baseline characteristics of the study
population, including medications used at baseline, have been de-
scribed.19 Mean (SD) age was 63.1 (8.6) years, mean (SD) body
mass index was 30.6 (5.3) kg/m2, 72% were male, 25.9% had eGFR
,60 mL/min/1.73 m2, 46.6% had a history of myocardial infarction,
10.1% had heart failure, and 5.5% had atrial fibrillation. At baseline,
81% of patients were on angiotensin-converting enzyme inhibitors
and/or angiotensin receptor blockers, 65% on b-blockers, 43% on
diuretics, and 6% on mineralocorticoid receptor antagonists.
Patient disposition in this trial has been described.19 Overall, 97%
of patients completed the study, with 25% of patients prematurely
discontinuing study drug. In both treatment groups, the most com-
mon reason for premature discontinuation of study medication was
adverse events.19 The median duration of treatment was 2.6 years
and the median observation time was 3.1 years. Final vital status
was available for 99% of patients.
Heart failure outcomes and
cardiovascular death in overall patient
population
The composite outcome of heart failure hospitalization or cardio-
vascular death occurred in a significantly lower percentage of pa-
tients treated with empagliflozin [265/4687 patients (5.7%)] than
placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95%
confidence interval, 95% CI: 0.55–0.79; P, 0.001)] (Figure 1A and
Table 1).19 The effect of empagliflozin on heart failure hospitalization
or cardiovascular death was consistent between doses (see Supple-
mentary material online, Table S1 and Figure S1) and across subgroups
defined by a variety of baseline characteristics including age, race,
eGFR, and use of glucose-lowering (including insulin) and cardiovas-
cular medications [including renin-angiotensin-aldosterone system
blockers, b-blockers, diuretics (including loop diuretics), and statins]
(Figure 2); subgroup analyses of 3-point major adverse cardiovascular
events and cardiovascular death by use of loop diuretics at baseline
are shown in Supplementary material online, Figure S2. The results
of sensitivity analyses were consistent with the primary analyses
(see Supplementary material online, Figure S3), and there were no dif-
ferences in censoring between empagliflozin and placebo. The me-
dian (interquartile range) of time to censoring for heart failure
hospitalization or cardiovascular death was 1167 (802–1297) days
in the placebo group and 1167 (805–1307) days in the empagliflozin
group. Empagliflozin also reduced the risk of the composite outcome
of hospitalization for heart failure or death from heart failure
(Table 1).
As previously reported, hospitalization for heart failure occurred
in a significantly lower percentage of patients treated with empagli-
flozin [126/4687 patients (2.7%)] than with placebo [95/2333
patients (4.1%)] [HR: 0.65 (95% CI: 0.50–0.85); P ¼ 0.002].19 The
effect of empagliflozin on this outcome was consistent across doses,
sensitivity analyses, and subgroups defined by baseline characteris-
tics (Figure 2; see Supplementary material online, Table S1 and
Figure S3). In the 126 patients with at least one heart failure hospital-
ization event in the empagliflozin group, 43 patients had 111 recur-
rent events (either heart failure readmission or cardiovascular
death), while in the 95 patients with at least one heart failure
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Table 1 Heart failure outcomes and all-cause hospitalization
Outcome Placebo (N5 2333) Empagliflozin (N 5 4687) HR (95% CI) P-value
n (%) Rate/1000
patient-years
n (%) Rate/1000
patient-years
Heart failure hospitalization or cardiovascular death 198 (8.5) 30.1 265 (5.7) 19.7 0.66 (0.55–0.79) ,0.001
Hospitalization for or death from heart failure 104 (4.5) 15.8 129 (2.8) 9.6 0.61 (0.47–0.79) ,0.001
Hospitalization for heart failure 95 (4.1) 14.5 126 (2.7) 9.4 0.65 (0.50–0.85) 0.002
Investigator-reported heart failurea 143 (6.1) 22.0 204 (4.4) 15.3 0.70 (0.56–0.87) 0.001
Investigator-reported serious heart failurea,b 136 (5.8) 20.9 192 (4.1) 14.4 0.69 (0.55–0.86) 0.001
All-cause hospitalization 925 (39.6) 183.3 1725 (36.8) 161.9 0.89 (0.82–0.96) 0.003
CI, confidence interval; HR, hazard ratio; MedDRA, Medical Dictionary for Regulatory Activities.
aBased on narrow standardized MedDRA query ‘cardiac failure’, which comprised these preferred terms: acute pulmonary oedema; cardiac failure; cardiac failure, acute; cardiac
failure, chronic; cardiac failure, congestive; cardiogenic shock; cardiopulmonary failure; left ventricular failure; pulmonary oedema; right ventricular failure.
bAdverse events reported as serious adverse events by investigator. Patients treated with at least one dose of study drug.
D. Fitchett et al.1528
hospitalization event in the placebo group, 43 patients had 115
recurrent events (see Supplementary material online, Table S2).
Information on readmission for heart failure is shown in Supplemen-
tary material online, Table S3. Among patients who were hospita-
lized for heart failure during the study, a smaller proportion of
patients treated with empagliflozin than with placebo died of cardio-
vascular causes [17 (13.5%) vs. 23 (24.2%)] (see Supplementary
material online, Table S2).
Consistent with the adjudicated results, the proportions of
patients with investigator-reported heart failure and with
investigator-reported serious heart failure were significantly lower
with empagliflozin than with placebo (Table 1). Loop diuretics
were introduced in a significantly lower proportion of patients in
the empagliflozin group than the placebo group [HR: 0.62 (95%
CI: 0.53–0.73); P, 0.001] (see Supplementary material online,
Figures S4 and S5). Empagliflozin also reduced the risk of the
composite outcomes of hospitalization for heart failure or introduc-
tion of loop diuretics [HR: 0.63 (95% CI: 0.54–0.73); P, 0.001]
and heart failure hospitalization or cardiovascular death or introduc-
tion of loop diuretics [HR: 0.64 (95% CI: 0.56–0.73); P, 0.001]
(see Supplementary material online, Figures S4 and S5). Further-
more, all-cause hospitalization occurred in a significantly lower
percentage of patients treated with empagliflozin than with placebo
(Figure 1B, Table 1; Supplementary material online, Figure S6).
As previously reported, empagliflozin was associated with
a significant reduction in cardiovascular death compared with
placebo, consistent across doses, sensitivity analyses, and patient
subgroups defined by a variety of baseline characteristics.19
Figure 1 (A) Time to first hospitalization for heart failure or cardiovascular death. (B) Time to first all-cause hospitalization. Cumulative inci-
dence function. Patients treated with at least one dose of study drug. HR, hazard ratio; CI, confidence interval.
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Outcomes in patients with vs. without
heart failure at baseline
At baseline, 244 (10.5%) patients in the placebo group and 462
(9.9%) patients in the empagliflozin group had investigator-reported
heart failure. Compared with patients without heart failure at base-
line, patients with heart failure at baseline were slightly older, had
a higher weight and body mass index, and a greater proportion
had eGFR ,60 mL/min/1.73 m2, a history of myocardial infarction
or atrial fibrillation, and were receiving insulin, b-blockers,
angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers, diuretics, and mineralocorticoid receptor antagonists
(see Supplementary material online, Table S4). Within the
subgroups by presence/absence of heart failure at baseline, baseline
characteristics were balanced between the empagliflozin and
placebo groups. Systolic and diastolic blood pressure, weight, and
haematocrit over the course of the study in patients with and with-
out heart failure at baseline are shown in Supplementary material
online, Figure S7.
Incidence rates for heart failure hospitalization or cardiovascular
death, hospitalization for heart failure, cardiovascular death, and
all-cause mortality were two- to six-fold higher in patients with
heart failure at baseline compared with patients without heart
failure at baseline (see Supplementary material online, Table S5).
However, the reductions in the risk of these outcomes with
Figure 2 Subgroup analyses of heart failure hospitalization or cardiovascular death and hospitalization for heart failure by baseline character-
istics. Patients treated with at least one dose of study drug. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, confi-
dence interval; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HR, hazard ratio; SBP, systolic blood pressure.
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Figure 3 Outcomes in patients with and without heart failure at baseline. Cox regression analysis. Patients treated with at least one dose of study drug. CI, confidence interval; HR, hazard ratio.
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empagliflozin were consistent in patients with and without heart fail-
ure at baseline (Figure 3). Categories of cardiovascular death in pa-
tients with and without heart failure at baseline are shown in
Supplementary material online, Table S6.
Safety and tolerability
In the overall patient population, the percentages of patients with
adverse events, serious adverse events, and adverse events leading
to discontinuation were similar in the empagliflozin and placebo
groups, but genital infections were more common in patients trea-
ted with empagliflozin than with placebo.19 Adverse events consist-
ent with oedema were reported in a higher proportion of patients
treated with placebo [216/2333 (9.3%)] than with empagliflozin
[212/4687 (4.5%)]. Adverse events consistent with volume deple-
tion were observed in similar proportions of patients in the placebo
[115/2333 (4.9%)] and empagliflozin [239/4687 (5.1%)] groups.
In patients with heart failure at baseline, the proportions of pa-
tients with severe adverse events, serious adverse events, and ad-
verse events leading to discontinuation were higher compared
with patients without heart failure at baseline in both treatment
groups. However, lower proportions of patients treated with empa-
gliflozin than with placebo had adverse events, serious adverse
events, and adverse events leading to discontinuation (see Supple-
mentary material online, Table S7).
Discussion
In the EMPA-REG OUTCOMEw trial, the SGLT2 inhibitor empagli-
flozin, given in addition to standard of care, reduced the risk of the
composite endpoint of hospitalization for heart failure or cardiovas-
cular death, as well as its individual components, in patients with
type 2 diabetes and established cardiovascular disease. Consistent
reductions were observed across subgroups of patients defined
by a variety of clinical characteristics, including the presence of heart
failure at baseline and the use of medications commonly used in the
treatment of patients with type 2 diabetes and/or heart failure, and
between the two dose groups. In addition, empagliflozin reduced
all-cause hospitalization, with both hospitalization for heart failure
and hospitalization for other causes contributing to this reduction.
The lower rate of introduction of loop diuretics in the empagliflozin
group is consistent with a reduced incidence of hospitalization
for heart failure. Importantly, prior to these findings, no glucose-
lowering drug had been shown to improve heart failure outcomes
in patients with type 2 diabetes. Indeed, the thiazolidinediones
and the DPP-4 inhibitor saxagliptin have been associated with in-
creased risk of heart failure hospitalization in patients with type 2
diabetes at high cardiovascular risk.22
Heart failure is a common comorbidity and a common cause of
hospitalization in patients with type 2 diabetes, presenting a high
medical need for effective therapies. Treatment of patients with
type 2 diabetes and heart failure presents challenges for physicians
due to a lack of evidence-based guidelines on the optimal manage-
ment of such patients. Guidelines published by the European Society
of Cardiology (ESC) in 201223 and by the ESC in collaboration with
the European Association for the Study of Diabetes (EASD) in
201324 recognized the lack of adequate evidence on the safety
and efficacy of drugs used to treat diabetes in patients with heart
failure, as well as the need for further research into whether
glucose-lowering therapies can reduce the progression of heart
failure.
Preventing hospital admission and improving survival are key
goals of the treatment of patients with heart failure.23 Importantly,
empagliflozin reduced hospitalization for heart failure, cardiovascu-
lar death, and all-cause mortality to the same extent in patients with
heart failure at baseline, who had high use of medications used to
treat heart failure, as in patients without heart failure at baseline.
Thus, the overall effect of empagliflozin on these important out-
comes was not predominantly driven by patients with heart failure
at baseline. Of note, patients who survived a hospitalization for
heart failure were at high risk of subsequent mortality. Similar obser-
vations were made in the SAVOR-TIMI 53 study, in which 26% of
patients hospitalized for heart failure died.7
Our study has several limitations. The diagnosis of heart failure at
baseline was based solely on the report of investigators according to
the narrow SMQ, with no measures of cardiac function or biomar-
kers, such as brain natriuretic peptide, recorded. However, given the
baseline characteristics of these patients, including the high use of
drugs to treat heart failure and the high incidence of hospitalizations
for heart failure and cardiovascular death, it is reasonable to assume
that this was indeed largely a population of patients with pre-existing
heart failure. The type of heart failure outcomes relative to ejection
fraction could not be assessed based on the data available; thus, we
cannot conclude on the applicability of these results with regard to
reduced or preserved ejection fraction heart failure. In addition, the
subgroup of patients with heart failure at baseline was relatively
small and several of our analyses were conducted post hoc. The
diagnosis of hospitalization for heart failure included the initiation
or up-titration of oral or intravenous diuretic medication rather
than the more stringent requirement of initiation of intravenous
diuretic medication such as used in another study.7 However,
patients hospitalized with heart failure had a high risk of mortality,
consistent with the diagnosis.
The effect of empagliflozin on heart failure hospitalization or car-
diovascular death and on all-cause hospitalization was observed
very early and was sustained throughout the trial. This suggests
that the benefit was not driven by an effect on atherosclerosis.
The mechanisms behind the effects of empagliflozin on heart failure
and cardiovascular death are unknown. Potential contributors in-
clude osmotic diuresis, effects on plasma volume and sodium reten-
tion with modulation of the cardio-renal axis,25,26 reductions in
arterial stiffness and the rate pressure product, indicating diminished
left ventricular afterload,18 reductions in weight and blood pressure
without increases in sympathetic nervous activity,27 reductions in
hyperglycaemia with concomitant reductions in insulin levels,28
and reductions in uric acid.
In this trial, empagliflozin reduced the risk of hospitalization for
heart failure or cardiovascular death by 34%, corresponding to a
number needed to treat to prevent one heart failure hospitalization
or cardiovascular death of 35 over 3 years. It remains unknown
whether the benefits on outcomes reported herein apply to patient
populations with other clinical characteristics.
In conclusion, in patients with type 2 diabetes and high cardiovas-
cular risk, empagliflozin, given in addition to standard of care,
reduced heart failure hospitalization and cardiovascular death,
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with a consistent benefit observed in patients with and without
heart failure at baseline.
Supplementary material
Supplementary material is available at European Heart Journal online.
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